[THE INVESTOR] Ildong Pharmaceutical announced on Sept. 1 that ID-RHT3201, a Lactobacillus rhamnosus composition developed on its own, was found to be effective for treatment of atopic disease in animal testing.

The South Korean pharmaceutical company has separated Lactobacillus rhamnosus IDCC 3201 from the intestines of infants, and tyndallized it for probiotic bacterium for those with atopic diseases.

After orally administering the composition to mice with atopic dermatitis caused by house dustmite, the blood level of Immunoglobulin E, a major indicator of the skin condition, declined, according to the results that was published in Microbiology and Immunology’s July issue.

By Hwang You-mee (glamazon@heraldcorp.com)